alvelestat

Small molecule

Also known as MPH-966

Partialsignal

Evidence outlook · lead readout

ASTRAEUS (NCT03636347) · Alpha 1-Antitrypsin Deficiency, Emphysema, COPD

The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.

ASTRAEUS (NCT03636347): This was a randomized, double-blind, placebo-controlled study in 99 adults with alpha-1-antitrypsin-related lung disease; both alvelestat doses significantly reduced a blood biomarker of neutrophil elastase activity compared with placebo. Because the primary measure was a laboratory biomarker rather than a direct measure of lung symptoms or function, this is supportive but not definitive clinical evidence.

Also in development:Alpha-1 Antitrypsin Deficiency · Phase 2

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (2)
Chronic Obstructive Pulmonary Disease
Phase 1/2 (3)
Other / comorbidity
NCT02669251 · National Cancer Institute (NCI)
2016-04-28 – 2027-12-01 · Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease, Bronchiolitis Obliterans Syndrome
What this study did
NCT03986086 · Nelson Chao
2021-09 – 2023-12 · Hematologic Malignancy
What this study did
NCT04539795 · University of Alabama at Birmingham
2021-01-25 – 2021-10-29 · Covid19
What this study did

Competitive landscape

This drug's own stage for Alpha-1 Antitrypsin Deficiency: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Alvelestat: this drugPhase 2Small moleculeNeutrophil elastasePartial signal
NCT03636347: Blood neutrophil elastase activity reduced from baseline: -83.5% (SD 56.4) at alvelestat 120mg (p=0.023) and -93.3% (SD 41.0) at 240mg (p<0.001); both doses significant vs placebo (p<0.01 and p<0.001 respectively).
FazirsiranPhase 3RNA / oligonucleotideSERPINA1not yet gradedNo reviewed efficacy summary in this indication
BEAM-302Phase 1/2Gene therapy / editingSERPINA1 PiZ mutation (E342K)not yet gradedNo reviewed efficacy summary in this indication
TSRA-196Phase 1/2Gene therapy / editingSERPINA1not yet gradedNo reviewed efficacy summary in this indication
WVE-006Phase 1/2RNA / oligonucleotideSERPINA1 Z-allele mRNA (ADAR-mediated editing)not yet gradedNo reviewed efficacy summary in this indication
KB408Phase 1Gene therapy / editingSERPINA1 (alpha-1 antitrypsin; gene replacement)not yet gradedNo reviewed efficacy summary in this indication
Efdoralprin Alfa
—(overall)
Protein / enzyme therapeuticAlpha-1 antitrypsin (AAT)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow alvelestat to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Phase 1/2Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease, Bronchiolitis Obliterans SyndromeActive not recruiting
Est. primary completion 2027-12-01 · NCT02669251 · CT.gov ↗
What to watch

See the full readout calendar ↗